sur INNATE PHARMA (EPA:IPH)
Innate Pharma to Present IPH4502 Clinical Data
Innate Pharma SA announced an event on November 18, 2026, in London, to discuss IPH4502, a novel Nectin-4 ADC. The presentation will cover findings from the Phase 1 clinical study, including safety and antitumor activity. Professor Yohann Loriot will provide clinical insights alongside Innate's management team. A live Q&A session will follow the formal presentations.
IPH4502 features a proprietary stable linker and payload designed to overcome limitations of current ADCs in urothelial cancer. It has shown potential in preclinical models resistant to existing treatments. The investigational product is not yet approved by regulatory bodies.
Innate Pharma remains committed to advancing innovative cancer immunotherapies, with IPH4502 as a key asset in its pipeline.
R. E.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de INNATE PHARMA